Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

60.17 +0.69 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,171,970
Open 60.20
Bid (Size) 58.50 (1)
Ask (Size) 60.15 (1)
Prev. Close 59.48
Today's Range 59.84 - 60.62
52wk Range 46.48 - 64.21
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years
Positive results from the HIMALAYA Phase III trial showed a single priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful... 
From Business Wire News Releases
IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically... 
From Business Wire News Releases

Performance

YTD
+3.19%
+3.19%
1 Month
+5.67%
+5.67%
3 Month
-1.72%
-1.72%
6 Month
+3.81%
+3.81%
1 Year
+15.18%
+15.18%

More News

Read More
CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
From Business Wire News Releases
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
From Business Wire News Releases
7 Bear Market Stocks to Buy If You See Trouble Ahead
Tags AZN SBUX JPM
From InvestorPlace
AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer
Tags General Biotech Health Care
From Benzinga
Death Cross Looms Over AstraZeneca Investors
Tags BZI/CROSS Benzinga Movers
From Benzinga
Is Ocugen Stock a Buy Now?
Tags JNJ MRNA Market News
From Motley Fool
3 Under-the-Radar COVID Stocks
Tags OPRX MDT GSK
From Motley Fool
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Tags IPOs Top Stories ASLN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.